Boronic acid hydrogel sensor for intravascular (arterial) blood glucose monitoring

Informazioni relative al progetto

Glucoset

ID dell’accordo di sovvenzione: 729375

DOI

10.3030/729375

Progetto chiuso

Data della firma CE 21 Maggio 2016

Data di avvio 1 Giugno 2016

Data di completamento 30 Novembre 2016

Finanziato da

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies

Costo totale

€ 71 429,00

Contributo UE

€ 50 000,00

Coordinato da

GLUCOSET AS
Norway

Periodic Reporting for period 1 - Glucoset (Boronic acid hydrogel sensor for intravascular (arterial) blood glucose monitoring)

Periodo di rendicontazione: 2016-06-01 al 2016-11-30

Sintesi del contesto e degli obiettivi generali del progetto

Poor glucose control in critically ill hospitalized patients leads to infections, deaths and large costs for hospitals. Currently, the only viable solution is to use manual point measurements of glucose for moderate glucose control. GlucoSet has developed a real-time arterial blood glucose sensor that will reduce the risk of harmful low glucose episodes, and make safe intensive insulin therapy possible. These two benefits are expected to significantly improve outcomes and reduce the length of stay for patients in the ICU. This is not only important for individuals, but also for society, as the need for intensive care is expected to outgrow supply in the next years, due to an aging population.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

The objective of this feasibility study is to validate and quantify GlucoSet’s competitive advantages, market size and IPR; to validate feasibility of mass production of product; and to set up a clinical and regulatory strategy for the product.

The study has confirmed GlucoSet's competitive advantage in a survey among European ICU managers; continuous monitoring through an indwelling arterial catheter was considered a must have and highly valuable. Conversely, the advantages of our direct competitors were not seen as necessary by a significant share of customers. The market size has been estimated at 1350 MEUR, and the company's IPR strategy has been validated by an external party. External parties also validated the feasibility of mass producing the product. Finally, a realistic and feasible clinical and regulatory strategy has been established.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

This study has confirmed that there is a need and a market for an arterial continuous glucose sensor. This is seen as highly unique by the market, and customers highlighted that the device was expected to improve quality of care.

When realized, the project will improve the efficiency and quality of ICUs in Europe and beyond, improving quality of life for individuals and reducing the cost of care for society.

The study has also confirmed that it is feasible to develop and manufacture the device in Europe, selling to an international market. In this way, the project is expected to be of significant value to society through job creation in several European countries.

Company logo